Mustang Bio Presents Updated P-I/II Trial Results of MB-106 for the Treatment of Waldenstrom Macroglobulinemia at EHA 2023
Shots:
- The updated results from an ongoing P-I/II trial evaluating MB-106 in patients with WM. The therapy is being developed in collaboration b/w Mustang & Fred Hutchinson Cancer Center to treat patients with r/r B-NHLs & CLL
- The results showed that 83% responded to treatment, incl. CR (2), VGPR (1), PR (1) & minor response (1), 1 patient experienced SD, patients remained in remission who achieved a CR for 22mos., IgM level decreased rapidly to the normal range, no patient has started additional anti-WM treatment after being treated with MB-106
- CRS were reported in 5 patients: 2 with grade 1, 3 with grade 2 while 1 experienced grade 1 ICANS & no grade 3 or 4 CRS or grade 2, 3, or 4 ICANS were seen. The therapy continues to demonstrate favorable safety & efficacy profile
Ref: GlobeNewswire | Image: Mustang Bio
Related News:- Mustang Bio Presented P-I/II Clinical Trial of MB-106 for Waldenstrom's Macroglobulinemia at 11th International Workshop
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
